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Value of refill measurement, saralasin test, and acebutolol
treatment in hypertension. The participation of the renin-angio-
tensin system in the origin of arterial hypertension can be eval-
uated by different methods. One can measure peripheral plasma
renin activity (PRA) under strictly controlled postures and diet-
ary sodium intake. The vasoconstrictor effect of angiotensin can
be indirectly determined through the fall of arterial blood pres-
sure due to the i.v. injection of a competitive antagonist of angio-
tensin H, saralasin, on a negative sodium balance. Both these
tests were performed in 24 hypertensive patients. We then stud-
ied their predictive value in relation to blood pressure response
to a 48 hour's oral administration of a beta blocker, acebutolol.
The results of PRA, saralasin test, and treatment by acebutolol
were later compared to the surgical outcome in 13 patients who
underwent renal artery repair. Blood pressure fall induced by
saralasin correlated well with peripheral PRA (r = 0.59, P <
0.01), and it predicted subsequent lowering of blood pressure un-
der acebutolol (r = 0.59, P < 0.01). The beta blocker treatment
was more efficient when PRA was higher (r = 0.62, P < 0.001).
On the whole, the results validate the concept of an anti-
hypertensive therapy, based on the different investigation meth-
ods of the renin-angiotensin system. Nevertheless, none of the
correlation coefficients obtained allow us to conclude that PRA
determination or a saralasin test would in a given patient foresee
the effectiveness of a beta-blocker treatment. Likewise, neither
the exploration of the renin-angiotensin system, nor the response
to a short-lasting beta-blocker therapy could precisely predict
the blood pressure results after renal artery surgery.
Valeur de Ia mesure de La rénine, du test a La pam Ia sine et du
traitement court per I'acébutolol dans l'hypertension. La parti-
cipation du système rënine-angiotensine dans Ia genèse dune hy-
pertension artérielle peut être dvaluée par diffdrentes méthodes.
On peut mesurer l'activité rénine plasmatique (PRA) dans le sang
veineux periphérique, dans des conditions de posture et d'apport
alimentaire en sodium strictement contrôlées. L'effet vasocon-
stricteur de l'angiotensine peut étre quantiflé indirectement
après induction d'un bilan sodé négatif par Ia mesure de la chute
tensionnelle induite lors de l'injection iv. d'un inhibiteur com-
pdtitif de l'angiotensine II, la saralasine. Les résultats de ces
deux tests ont été compares chez 24 hypertendus et on a étudié
leur valeur predictive de la reponse tensionnelle a l'adminis-
tration orale pendant 48 heures d'un béta-bloquant, I'acebutolol.
Received for publication November 29, 1977
and in revised form July 25, 1978.
0085-2538/7910015-0176 $01.80
© 1979 by the International Society of Nephrology
Les résultats de I'PRA, du test a la saralasine et du traite-
ment court par l'acébutolol ont éte compares chez 13 de ces
malades, aux résultats de Ia chirurgie de l'artère rénale. La
chute de la pression artérielle induite par Ia saralasine est bien
correlëe a 1'PRA pdriphdrique (r = 0.59, P <0.01) et prédit la
chute ultérieure de la pression artèrielle sous l'influence de
l'acebutolol (r = 0.59, P < 0.01). Le traitement bêta-bloquant est
d'autant plus efficace que l'PRA est élevée (r = 0.62, P < 0.001).
L'ensemble des résultats valide donc le concept d'une therapeu-
tique de l'hypertension artérielle reposant sur les diffCrentes me-
thodes d'investigation du système rénine-angiotensine. Néan-
moms, aucun des coefficients de correlation obtenus ne permet
de conclure que Ia mesure de l'PRA ou que le test ala saralasine
puisse permettre chez un individu donnd de prévoir a coup sür
l'efficacitè d'un traitement béta-bloquant. De la méme facon, ni
les explorations du système rénine-angiotensine, ni la rdponse a
un traitement béta-bloquant de courte durée, ne prédisent avec
suffisamment de precision les rèsultats tensionnels de Ia chi-
rurgie de l'artère rénale.
Further knowledge of the physiopathology of hy-
pertension could lead to medical treatment which
would be adjusted to the findings in each hyperten-
sive patient [1, 2]. The presence of a positive sodium
balance or the existence of either an abnormally
stimulated renin-angiotensin system or one not ad-
justed to the state of sodium balance can lead to
prescription of sodium depletion [2], the use of ther-
apy to decrease the activity of the renin-angioten sin
system [3—61, or to renal surgery [7]. The view that
each case should be treated individually requires
the improvement of methods to quantify the various
parameters potentially responsible for blood pres-
sure elevation.
In this study, we compared three methods which
assess renin-angiotensin participation in blood pres-
sure elevation: plasma renin activity (PRA) mea-
surements, arterial blood pressure response to i.v.
administration of saralasin, and the response of
blood pressure to a 48-hour's oral treatment with a
beta blocker, acebutolol (acebutolol test). The re-
sults obtained were analyzed from a theoretical
stand-point as well as for their practical value in the
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diagnosis and treatment of "renin-dependent hyper-
tension."
Methods
Patients. Twenty-four patients with permanent
hypertension were chosen for the study. They were
sent by their attending physician who was fully
aware of previous work in this field [8-12]. Ages
ranged from 17 to 53 years. Eighteen patients had
confirmed renal artery disease (rapid sequence i.v.
pyelography and renal arteriography), and six pa-
tients had essential hypertension. All patients were
hospitalized 3 weeks after their withdrawal from all
antihypertensive medication. On admission, they
were placed on a diet of 110 mEq of sodium per day,
and a 3-day's control period was performed.
We decided to operate on all patients with renal
artery disease, regardless of the results of pharma-
cologic tests, unless their clinical situation was con-
sidered to be a contraindication. Surgery was con-
sidered successful when the patient became normo-
tensive without any drugs. Postoperative condition
was considered improved when hypertension per-
sisted but was less severe (diastolic pressure, at
least 20 mm Hg lower than preoperative levels) and
more easily controlled medically.
Protocol. Patients were investigated during a
constant sodium intake of 110 mEq of sodium daily.
Sodium and potassium urinary excretions were
measured daily.
Saralasin test. This test was performed on the 4th
hospitalization day. Mean natriuresis before diuret-
ics was 104.2 23.6 mEq/24 hr. Furosemide (0.5
mg/kg body wt) was given i.v. 4 hours before the
study. Natriuresis induced during this period was
159.0 114.0 mEq/4 hr. The patients then lay
down, and blood pressure was recorded every 2 mm
automatically by an arteriosonde (Roche) beginning
1 hour before saralasin, during the infusion, and for
1 hour after. Saralasin was given at increasing doses
(1, 2, 4, and 10 /Lg/kg/min). Each dose was given for
10 mm, and infusion was continued during 30 mm at
the highest concentration or at the dose producing a
significant decrease of diastolic pressure. A re-
sponse was considered positive when diastolic pres-
sure decreased more than 8 mm Hg according to
Streeten et al [8, 9]. Basal diastolic blood pressure
was calculated as the mean of measurements ob-
tained 10 mm before starting saralasin infusion.
Blood samples were drawn for the measurement of
PRA and plasma aldosterone before, during, and 1
hour after infusion. Sodium loss induced by furose-
mide was replaced by isotonic saline on the 5th day.
Then, on the 6th day, a short treatment by beta
blockers was started.
Acebutolol test. This test was begun on the 6th
hospitalization day. Mean natriuresis was 90.2
40.5 mEq/24 hr on the initial day. A total dose of 2.0 g
of acebutolol was given over 48 hours, as already
described [13]. Blood pressure was measured four
times in the recumbent and upright positions, on the
morning before starting the test and on the morning
after the last dose of acebutolol. The variability of
diastolic pressure measurement in a group of 50 pa-
tients was 6.0 3.6 mm Hg. We thus considered a
response to be positive when diastolic pressure de-
creased more than 10 mm Hg in the supine position
(blood pressure change SD).
Determination of plasma renin activity. PRA was
measured while the patient was on a diet of 110
mEq of sodium per day and in the upright position
after 1 hour of active ambulation. Blood samples
were drawn on the 3rd hospitalization day and on
the 6th and 8th day, before the first and after the last
dose of acebutolol was given.
In 8 of 13 patients who were submitted to sur-
gery, renal vein determinations were performed
during the control period. Neither tilting nor stimu-
lation by diuretics or hydralazine was used.
Analytical methods. Plasma aldosterone and
PRA were measured by radioimmunoassay as pre-
viously described [14, 15]. In 20 normal subjects,
aged 25 to 55 years, upright PRA was from 0.7 to 3
ng/mllhr for a natriuresis of 99.5 21.8 mEq/24 hr,
whereas upright plasma aldosterone ranged from 10
to 35 ng/l00 ml. The interassay variation of PRA for
a control plasma measurement was 10.3 7.7%.
All results are given as mean SD.
Results
Plasma renin activity. PRA in the upright posi-
tion was 3.39 4.2 ng/mllhr on the 3rd hospital-
ization day and 3.89 5.6 nglmllhr in the same posi-
tion on the 6th day, 48 hours after saralasin test and
sodium replacement. Both measurements were sig-
nificantly correlated (r = 0.99, P < 0.001). The val-
ue of PRA in the recumbent position on day 4 of the
hospitalization, 4 hours after the injection of furose-
mide, was 2.99 4.2 ng/mllhr. The two methods for
stimulating renin secretion, upright position under
normal sodium diet and recumbent position under
sodium depletion, gave highly correlated values (r
= 0.95, P < 0.001).
Natriuresis. Mean natriuresis before sodium de-
pletion was 104.16 23.55 mEq/24 hr. Injection of
furosemide (0.5 mg/kg body wt) induced a mean so-
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Table 1. Heart rate, systolic and diastolic blood pressure (BP), PRA, and plasma aldosterone before, during, and 1 hour after saralasin
infusiona
Before During After 1 hour
All Renal Ess. All Renal Ess. All Renal Ess.
patients art. dis. hyp. patients art. dis. hyp. patients art. dis. hyp.(N = 24) (N = 18) (N = 6) (N = 24) (N = 18) (N = 6) (N = 24) (N = 18) (N = 6)
Heart rate 75.7
16.1
76.9
18.7
72.0
11.4
74.4
16.3
76.2
17.7
69.2
10.9
75.7
16.0
77.6
16.8
70.2
12.6
Systolic BP 164.8
24.4
165.3
25.9
163.3
21.7
152.5c
21.5
152.1c
22.8
153.8
16.8
162.9
23.7
161.9
23.9
166.1
25.3
DiastolicBP 111.5
15.2
108.8
14.7
119.4
14.8
102.8e
4.8
997c
14.4
111 9l
13.9
112.7
14.9
109.7
14.8
121.5
12.8
PRA,ngin11'hr1 2.9
4.2
3.3
4.7
2.0
1.4
4.6
6.2
5.2
6.8
2.5
2.4
4.3
4.9
5.0
5.3
2.25
2.1
Plasma aldosterone,
ngIIOOml 11.8
7.0
12.3
7.7
10.5
4.5
12.8
6.9
12.5
6.5
13.6
8.6
14.0
10.1
14.3
11.4
13.0
5.7
Abbreviations used are: art. dis., arterial disease; ess. hyp., essential hypertension.
P < 0.05.
P <0.001.
dium loss of 159.0 114.0 mEq in 4 hours. The de-
gree of natriuresis was neither correlated to initial
PRA nor to the blood pressure response to sarala-
sin.
Results of saralasin test. Diastolic and systolic
arterial pressure decreased significantly under sa-
ralasin infusion. When the infusion was stopped,
blood pressure increased to its control value. The
lowering of blood pressure was not accompanied by
acceleration of heart rate. PRA rose during the
course of saralasin infusion, whereas plasma al-
dosterone remained unchanged (Table 1). The
all r = 0.59, P <0.01
Ar 0.75,P<0.001
• r = 0.35, P = NS
A
PRA,ngmlhr1
Fig. 1. Relationship between control PRA and the change in
diastolic blood pressure during saralasin infusion. Patients with
renal artery disease are denoted by triangles (A) (N = 18).
Those with essential hypertension are denoted by circles (.)(N = 6).
lowering of blood pressure correlated significantly
with log PRA measured immediately before starting
the infusion (r = 0.59, P < 0.01) (Fig. 1), whereas
no correlation was found between the change in
PRA and the decrease of blood pressure. When
analysis of results was done separately for patients
with renal artery disease and patients with essential
hypertension, significant decreases of diastolic
blood pressure were seen in both groups (Table 1).
Nevertheless, the correlation between PRA and de-
crease in diastolic blood pressure was only found in
patients with renal artery disease (Fig. 1). When pa-
tients on a I 10-mEq/day sodium intake were classi-
fied according to PRA measured in the upright posi-
tion, those hypertensive patients with high renin
showed a greater drop (P < 0.05) in diastolic pres-
sure than did the group of patients having a normal
or low renin activity (Fig. 4).
Results of acebutolol test. The mean decrease in
diastolic blood pressure from 114.1 14.1 to 105.5
13.5 mm Hg (Table 2) produced by acebutolol
was highly significant (P < 0.001). The administra-
tion of acebutolol lowered PRA from 3.9 5.6 to
—15 0.84 0.80 nWmllhr (P <0.02) (Table 2), and this
decrease correlated with the fall of diastolic blood
pressure (r = 0.62, P < 0.001). The blood pressure
drop of high-renin patients was significantly greater
(P < 0.02) than was that of normal- and low-renin
patients (Fig. 4). When patients with renal artery
disease and patients with essential hypertension
were considered separately, the decrease of diastol-
ic pressure was significant (P < 0.001) for the first
group. A significant correlation was found between
A
20 10 2AI I I
A
A
A A
AAS
A
A
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Table 2. Heart rate, systolic and diastolic blood pressure (BP), PRA, and plasma aldosterone before and after acebutolol administrationa
Before 48 hours after
All
patients(N = 24)
Renal
art. dis.
(N = 18)
Ess.
hyp.(N = 6)
All
patients(N = 24)
Renal
art. dis.
(N = 18)
Ess.
hyp.(N = 6)
Heart rate
Systolic BP
DiastolicBP
PRA, ngml'hr'
Plasmaaldosterone,ng/lOOml
76.0 13.4
187.5 32.2
114.1 14.1
3.8 5.6
32.2 25.1
77.6 12.5
183.4 31.3
113.2 14.1
3.9 6.0
36.8 28.0
71.3 16.3
176.0 15.8
120.7 10.75
2.8 1.9
32.0 11.7
67.7C 7.4
l65.6' 27.8
l05.5' 13.5
Ø84b 0.80
176b 6.9
67.9' 7.4
l67.4C 30.5
102.5" 12.9
0.8 0.7
15•9b 6.2
67.0 8.0
16Ø4b 18.5
114.0 12.1
0.78e 1.0
22.8 6.8
a See Table 1 for abbreviations used.p < 005
P < 0.01.
"P < 0.001.
upright PRA and decrease in diastolic blood
pressure (P < 0.001) (Fig. 2) in the group with
renal artery disease.
Comparison of changes in blood pressure under
saralasin and under acebutolol. Diastolic blood
pressure decrease induced by the administration of
saralasin correlated significantly with that produced
by acebutolol (r = 0.59, P < 0.01) (Fig. 3). An
equivalent correlation was found among the 18 pa-
tients with renal artery disease (r = 0.70, P < 0.01).
Prediction of the hypotensive response to admin-
istration of a beta blocker. This prediction can be
made either from PRA measurement or from the re-
sponse to saralasin infusion. (a) Prediction from
PRA measurement. As has been reported [13], the
decrease in blood pressure by beta blockers corre-
lates with initial PRA values. In our group of pa-
tients, the classification into low- (3 patients), nor-
mal- (10 patients), and high-renin (11 patients)
groups showed (Fig. 4) that the decrease was signif-
icantly higher in the group with a high PRA (P <
0.02). The fall in blood pressure correlated with ini-
tial PRA (r = 0.62, P < 0.001) (Fig. 2). (b) Predic-
tion regarding the response to saralasin. Among 12
responders to saralasin, 9 patients showed a signifi-
cant decrease of diastolic blood pressure under ace-
butolol. Among the 10 acebutolol responders, 8 pa-
tients had a positive response to saralasin test.
Prediction of the hypotensive response to surgi-
cal repair. Of the 18 patients with renal artery dis-
ease, 13 were submitted to surgery (8 venous grafts,
2 terminoterminal anastomoses, and 5 nephrecto-
mies). They have all been followed for at least 12
months. According to the criteria previously estab-
lished, 11 patients (patients 1, 6, 8, 10—13) (Tables 3
and 4) achieved a favorable response to surgical
therapy and were categorized as having proven
renovascular hypertension. Patients 14, 15, and 16
refused surgery. Medical treatment was preferred
for patients 17 and 18 for the following reasons: pa-
tient 17 had a Takayasu, patient 18 had a long-dat-
ing hypertension and an operated aortic coarctation
besides her renal artery stenosis. Therefore, in the 5
patients in whom surgery was not performed, reno-
vascular hypertension could be suspected but was
not proven. Though the different explorations done
in patients 7 and 9 pointed to a surgical failure, they
were operated on to preserve renal function. Surgi-
cal therapy was technically successful; patency of
both grafts was seen on postoperative arteriogra-
phy.
The different methods used to explore the partici-
pation of the renin-angiotensin system in hyper-
A20 10 2
A
I I AA A
A
AA• A
A LA.
A
alt r = 0.62, P <0.001 ALA r = 0.70, P <0.001
• r = 0.64, P = NS
A A
A
—5
0
0
0
—15
PRA,ngm/' -hr'
Fig. 2. Relationship between control PRA and the change in
diastolic blood pressure during acebutolol administration. Pa-
tients with renal artery disease are denoted by triangles (A)(N = 18). Those with essential hypertension are denoted by cir-
cles (.) (N = 6).
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all r 0.59,1P <0.01 £
Ar 0.65,P <0.01
Sr 0.40,P = NS
tension associated with renal artery disease show,
in this study, that renal vein renin determination is
very reliable (Table 4).
Discussion
In this study, we compared three methods which
can be used for exploring the participation of the
renin-angiotensin system in the etiology of high
blood pressure. These explorations could aid in im-
portant therapeutic decisions [13, 16—18], surgery,
or choice of an antihypertensive drug. A significant
correlation was found between all three methods,
and all of them gave useful information as to the
renin-angiotensin system's role in high blood pres-
sure.
Our results showed that the higher the PRA, the
better the response to saralasin and acebutolol (r =
0.59, r = 0.62, respectively), and the greater the
lowering of blood pressure under saralasin, the
greater the efficiency of acebutolol (r = 0.59). These
results are pertinent when all 24 patients are ana-
lyzed as an homogenous group. The analysis of
each group separately shows that correlations are
very significant in the 18 patients with renal artery
disease. The lack of correlation in the essential hy-
pertension group could be explained by the reduced
number of patients.
On the other hand, when we consider the individ-
ual patient, none of the three methods gave an accu-
rate physiopathologic classification of his hyper-
tension, nor did it indicate an adequate therapeutic
choice. Although the significant correlations found
justify the reasoning which led to these studies, in
practice none of the three tests gave a definite re-
sponse which could guide the treatment of the pa-
tient studied. The difficulties encountered in apply-
ing the results of a group of patients to a single pa-
tient can be explained in many ways.
First, the variability of PRA measurement is an
important factor despite precaution taken. The
method used for PRA measurement is sensitive
enough to detect easily low PRA [14, 191. So-
dium balance was carefully controlled, and PRA de-
terminations were made in an equilibrium state un-
der a moderately salted diet (UNa V, 104.16 29.5).
No previous acidification of plasma was liable to al-
ter the results through the activation of an inactive
form of plasma renin [19, 20]. However, when PRA
was measured twice in the same patient, although
the results correlated well (r = 0.99), they were not
strictly equivalent, the variability between both re-
nm measurements being 0.62 1.48 ng/ml!hr. This
variability is only one of the factors which hinder
easy distinction between low, normal, and high
PRA. Another limitation is the existence of a con-
tinuous logarithmic-Gaussian distribution of renin
values [211, which renders the individualization of
groups highly arbitrary. In addition, the definition
of limits is too precise when the variability of the
measurement is taken into account, and the criti-
cisms of Marks and Maxwell of renal vein renin de-
termination can be applied in extenso to the periph-
eral renin assay [22]. A single PRA determination
cannot on its own predict surgical curability in a
renovascular hypertensive patient [23, 24] nor can
the blood pressure response to the administration of
a beta-blocker [13].
Fig. 4. Diastolic blood pressure changes induced by saralasin
and acebutolol in regards to PRA levels. N denotes the number
of patients.
A
A
—20 —10 £
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A
A
A
A
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0
.00
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5-
—15
C)
0
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C
—25
A
Diastolic BP (saralasin), mm Hg
Fig. 3. Relationship between changes in diastolic blood pressure
induced by saralasin and acebutolol. Renal artery disease is de-
noted by A (N = 18); essential hypertensive by • (N 6).
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Table 3.Clinical data in 18 cases of suspected renovascular hypertension
Duration of
Patient Age hypertension Follow-up
no. Diagnosisa yr months Operation Status months
1 Stenosis R, FMD 40 36 Termino-terminal anastomosis Cured 22
2 Stenosis R, FMD 25 36 Termino-terminal anastomosis Cured 22
3 Stenosis L, FMD 28 36 Venous graft Cured 17
4 Stenosis R, FMD 26 4 Venous graft Improved 12
5 Stenosis L, Takayasu 43 4 Nephrectomy Cured 22
6 Stenosis B, Takayasu 25 24 R. venous graft and L. nephrectomy Improved 12
7 Stenosis R, AS 48 12 Venous graft Unchanged 18
8 Stenosis B, AS 50 12 Venous graft Cured 8
9 Stenosis R, AS 39 12 Venous graft Unchanged 14
10 Stenosis R, AS 49 96 Venous graft Improved 16
11 Stenosis L. inferior pole vessel 27 24 Heminephrectomy Improved 22
12 R renal small artery and kidney 32 7 Nephrectomy Cured 12
13 Thrombosis R, nonfunctioning R kidney 27 12 Nephrectomy Improved 6
14 Stenosis L, AS 51 16 Refused — —
15 Stenosis B, FMD 51 24 Refused — —
16 R renal small artery and kidney 31 84 Refused — —
17 Stenosis B, Takayasu 18 12 Nonsurgical — —
18 Stenosis L, aortic coarctation 42 32 Nonsurgical — —
a Abbreviations used are: R, right; L, left; B, bilateral; FMD, fibromuscular disease; AS, atherosclerosis.
The saralasin test was performed after moderate der any subject sensitive to renin-angiotensive sys-
sodium depletion to avoid the agonistic properties tern inhibition [10, 25]. A fixed diuretic dose does
of Sar1, A1a8-angiotensin II. Studies on renin-angio- not produce a strictly superimposable natriuretic ef-
tensin system inhibition in man [10, 25-27] and in fect from one patient to another, as is shown by the
animals [281 have shown that even in the absence of dispersion of natriuresis (159 114 mEqI4 hr) ob-
arterial hypertension, the role of the renin-angioten- tamed after furosemide injection. The exact defini-
sin system in blood pressure control is greater when tion of the negative sodium balance is rendered dif-
the sodium balance is negative. Sodium depletion ficult by this variability. Under these conditions,
preceding saralasin infusion is an arbitrary measure the test explored the participation of the renin-an-
since a sufficient negative sodium balance can ren- giotensin system in blood pressure maintenance at a
Table 4. Clinical data in 18 cases of suspected renovascular hypertensiona
Patient PRA Renal vein MAP MAP Preop Postop Postop BP
no. ngmf1hr1 renin ratio (saralasin) (acebutolol) BP BP (with drugs)
0.56 ND — 0.50 + 4.40 165/115 140/90 —
2 1.54 1.50 + 0.34 — 1.00 155/109 120/80 —
3 1.51 1.50 —13.70 —15.00 197/108 143/73 —
4 1.41 1.86 — 2.13 —13.37 170/110 130/90 —
5 3.20 ND —27.40 — 5.80 155/104 110/70 —
6 1.66 ND — 3.20 —12.80 194/113 150/90 —
7 1.70 ND + 1.00 — 8.90 175/103 160/110 160/95
8 4.00 1.50 —15.22 —10.63 196/111 140/88 —
9 1.58 1.23 + 0.56 — 1.67 158/113 150/100 150/100
10 3.20 1.50 —13.20 —18.37 244/148 150/104 140/104
11 2.70 1.07 —10.70 —12.70 159/114 140/105 110/70
12 27.80 1.50 —24.66 —38.00 195/133 100/80 —
13 3.12 ND — 8.17 —13.67 153/115 118/104 —
14 4.00 3.98 —16.83 —15.50 213/148 — —
15 1.90 1.23 —12.14 + 0.90 145/100 — —
16 0.56 1.21 — 1.63 — 7.83 146/115 — —
17 3.16 ND —20.83 — 8.00 238/127 — —
18 2.33 6.88 —19.26 —33.34 210/120 — —
a Abbreviations used are: AMAP, variations in mean arterial pressure; preop and postop, preoperative and postoperative, respective-
ly; ND, not determined.
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given sodium balance, more so than it did the role of
the system under basal conditions.
The blood pressure response to acebutolol ad-
ministered during 48 hours has the practical interest
of predicting the long-term efficacy of a beta-block-
ing treatment. Among 15 essential hypertensive pa-
tients, the correlation between a 2-day trial re-
sponse and the response after 45 days of medication
was highly significant (r = 0.81, P < 0.001) (Du-
crocq et al, unpublished data). The attribution of
the blood pressure fall produced by acebutolol to
renin-angiotensin system blockade is, however, an
insufficient explanation, since many possible mech-
anisms can be evoked to explain the antihyperten-
sive effect of beta blockers [3-6]
The significant correlations observed between the
saralasin test and PRA on the one hand and the ace-
butolol test on the other confirmed the concept that
the renin-angiotensin system can be inhibited at the
level of angiotensin-JI receptor or at that of renin
secretion. An interesting application of this concept
is the prediction of acebutolol responsiveness pre-
dicted by saralasin test. Previous work done by
Geykes et al [291 had shown a significant correlation
between changes in blood pressure after saralasin
administration and those induced by propranolol
only during sodium depletion (15-mEqlday diet, 240
mg of furosemide, and 100 mg of triamterene) when
PRA values rose. They did not find a correlation
between changes induced by saralasin and propran-
olol when a 60-mEq/day diet was maintained. They
concluded that sodium depletion induced renin de-
pendency of blood pressure in all patients. In our
study, such a significant correlation could be found
in the absence of sodium depletion during acebuto-
lol treatment and mild sodium depletion during sa-
ralasin administration. The degree of significance of
the saralasin test under the conditions used in this
study, however, makes it insufficiently reliable for a
given patient. Indeed, Fig. 3 shows the large indi-
vidual variations of blood pressure decrease under
the two different inhibitors of the renin-angiotensin
system.
The 24 patients who benefited from the test were
chosen among other hypertensive patients at the
request of their attending physician, who was fully
aware of previous work in this field [8-121. This ex-
plains the high proportion of renovascular hyper-
tension. In this disease, the saralasin test supplied
insufficient information, since it was not able to rec-
ognize all cases of renovascular hypertension (pa-
tients 1, 2, 4, 6), nor did it give an accucate index of
surgical curability.
In fact, when surgical results were analyzed, two
cases of fibromuscular disease of the renal artery
must be considered. Both (patients 1, 2, Tables 3
and 4) were normalized by surgery, although nei-
ther patient showed a fall in blood pressure with sa-
ralasin administration after sodium depletion, nor
after acebutolol administration under normal so-
dium diet. Similar cases of fibromuscular diseases
have already been published [30, 31], and they sug-
gest that a negative response to saralasin adminis-
tration is not sufficient evidence to discount further
investigation for renovascular hypertension in
young subjects, nor on a theoretical level is it suf-
ficient to affirm that the renin-angiotensin system
does not participate in blood pressure elevation in
those cases.
On an individual basis, the results obtained in this
study do not fully support the clinical interest which
some authors have shown in saralasin [8, 9, 11, 16,
22, 23]. Moreover, none of the three tests per-
formed in this study perfectly achieved the pro-
posed aims: (1) accurate evaluation of the renin-
angiotensin system's role in blood pressure eleva-
tion in a given patient and (2) choice of therapeutic
conduct based on these results. It is possible that
renin-angiotensin system blockade at other levels
might give information which is more precise and
less subject to criticisms [25, 26, 32—34].
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